Jefferies Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.27M Buy
25,628
+10,128
+65% +$2.2M 0.04% 339
2026
Q1
$2.62M Buy
+15,500
New +$2.68M 0.02% 522
2025
Q3
Sell
-2,500
Closed -$261K 1454
2025
Q2
$261K Buy
+2,500
New +$265K ﹤0.01% 1066
2025
Q1
Sell
-40,700
Closed -$3.44M 1620
2024
Q4
$3.44M Buy
+40,700
New +$3.74M 0.02% 484
2024
Q3
Sell
-15,859
Closed -$1.28M 1438
2024
Q2
$1.28M Sell
15,859
-316,907
-95% -$23.5M 0.01% 671
2024
Q1
$26.6M Sell
332,766
-230,569
-41% -$19.4M 0.25% 66
2023
Q4
$44.8M Buy
563,335
+10,140
+2% +$678K 0.29% 47
2023
Q3
$38.7M Buy
+553,195
New +$41.4M 0.35% 39

Other funds holding AXSM

Jefferies Financial Group's AXSM Position: Q2 2026 in Review

Jefferies Financial Group increased its Axsome Therapeutics (AXSM) stake by 65% in Q2 2026, buying an estimated $2.2M and bringing the position to 25,628 shares worth $6.27M. The position accounts for 0.04% of the portfolio, ranked #339.

Jefferies Financial Group first reported a position in AXSM in Q3 2023 and has held it in 8 quarters since. The position peaked at $44.8M in Q4 2023. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Jefferies Financial Group held 25,628 shares of Axsome Therapeutics worth $6.27M as of Q2 2026.
  • Jefferies Financial Group bought 10,128 Axsome Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Axsome Therapeutics made up 0.04% of Jefferies Financial Group's portfolio in Q2 2026, its #339 holding.
  • Jefferies Financial Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Jefferies Financial Group's Axsome Therapeutics position peaked at $44.8M in Q4 2023.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.